Curated News
By: NewsRamp Editorial Staff
January 13, 2025
Cognition Therapeutics Advances Drug Candidate CT1812 to Phase 3 After Promising Phase 2 Results
Discuss on Reddit
LinkedIn
Substack
Telegram
GithubTLDR
- Cognition Therapeutics' drug candidate CT1812 shows promising results in phase 2 trial, advancing to phase 3, offering a competitive edge.
- Cognition Therapeutics focuses on developing oral medications for neurodegenerative disorders like dementia, with recent success in treating DLB and Alzheimer's.
- Cognition Therapeutics' breakthrough in dementia treatment offers hope for patients, potentially improving lives and advancing healthcare for a better tomorrow.
- Cognition Therapeutics' research on CT1812 provides insight into innovative approaches for combating neurodegenerative diseases, sparking curiosity and learning opportunities.
Impact - Why it Matters
This news highlights significant progress in the development of potential treatments for neurodegenerative disorders, offering hope for patients and their families. It signifies a step forward in addressing critical forms of dementia, potentially improving the quality of life for those affected.
Summary
Lisa Ricciardi, president and CEO of Cognition Therapeutics (NASDAQ: CGTX), discussed the company's breakthrough in developing oral medications to treat neurodegenerative disorders like dementia with Lewy bodies and Alzheimer's. Their drug candidate, CT1812, showed promising results in a phase 2 trial, moving to phase 3.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Cognition Therapeutics Advances Drug Candidate CT1812 to Phase 3 After Promising Phase 2 Results
